Research programme: enzyme targeted therapeutics - Nitrase Therapeutics
Latest Information Update: 05 Jun 2024
At a glance
- Originator Nitrome Biosciences
- Developer Nitrase Therapeutics
- Class Antineoplastics; Antiparkinsonians; Small molecules
- Mechanism of Action Alpha-synuclein inhibitors; Enzyme modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Parkinson's disease; Solid tumours
Most Recent Events
- 05 Jun 2024 Preclinical trials in Haematological malignancies in USA (unspecified route) before June 2024 (Nitrase Therapeutics pipeline, June 2024)
- 05 Jun 2024 Preclinical trials in Parkinson's disease in USA (unspecified route) before June 2024 (Nitrase Therapeutics pipeline, June 2024)
- 05 Jun 2024 Preclinical trials in Solid tumours in USA (unspecified route) before June 2024 (Nitrase Therapeutics pipeline, June 2024)